Introduction
============

Motor neurons (MNs) are differentiated cells that control voluntary actions and are affected primarily by a wide spectrum of neurological disorders, generally indicated as motor neuron diseases (MNDs). MNDs may present with a range of symptoms deriving from muscular weakness/atrophy and leading to death \[[@B1]\]. Currently, no effective treatment exists for these illnesses.

Every year, MNDs affect approximately 2 new cases per 100,000 people, and the prevalence of these disorders is about 5 to 7 cases per 100,000 \[[@B2]\]. MNDs are usually more common in men than women, and the incidence rate is 2:1 \[[@B3]\]. The life expectancy of patients with MND is quite variable: for about half of these disorders, death occurs 3 to 5 years from the onset of symptoms, but some people may live for more than 10 years, whereas in other cases the disease can be very rapidly progressive. Reasons accounting for such variability remain poorly understood.

MNDs can be classified in relation to the subpopulation of MNs affected mainly by the disease process as spinal muscular atrophy (SMA), progressive muscular atrophy, spinobulbar muscular atrophy (or Kennedy's disease), and hereditary motor neuropathies involving lower MNs. Among them, SMA is the most common disease during childhood \[[@B4]\]. SMA is an autosomal recessive disease: the majority of patients with SMA carry mutations in the *SMN1* gene (survival motor neuron 1), resulting in the selective degeneration of lower α-MNs. The *SMN2* gene, an *SMN1* homologue, compensates for the abnormal production of SMN1 protein, and its levels of expression correlate with disease severity \[[@B5]\]. The pathology involves spinal cord MNs causing their degeneration and ultimately death.

Upper MNs are more vulnerable in primary lateral sclerosis, hereditary spastic paraplegias, and spinal muscular atrophy with respiratory distress type 1 \[[@B6]\].

Finally, disease processes that affect both upper and lower MN populations, such as amyotrophic lateral sclerosis (ALS), can be reported. ALS is mostly sporadic (SALS), and familial forms of ALS (FALS) account for 10% of cases \[[@B7]\]. *C9orf72* expansion has been observed in the majority of FALS cases \[[@B8]\], but many other genes have been involved in ALS etiopathogenesis such as Tar-DNA-binding protein 43 (*TDP-43*), fused in sarcoma protein (*FUS*) \[[@B9]\], and superoxide dismutase (*SOD1*) \[[@B10]\]. ALS incidence is 1 to 2 per 100,000 persons every year, and the age of onset is around 50 to 60 years: symptoms develop from paralysis to death within 2 to 5 years from the diagnosis \[[@B7]\].

Pathological mechanisms underlying the onset of ALS and generally MNDs are largely unknown. Many factors seem to be involved in the process with different contributions from environmental and genetic factors \[[@B11]\].

Stem cell-derived MNs represent a promising research tool in disease modeling, drug screening, and development of therapeutic approaches for MNDs and spinal cord injuries \[[@B12],[@B13]\]. They could provide a replacement for dying cells and a trophic support within the central nervous system (CNS) \[[@B12]\].

In regard to the latter, stem cells may be supportive for endogenous cells modulating the diseased microenvironment by providing neurotrophic factors and scavenging toxic catabolites.

Particularly in the case of neurodegeneration, the potential positive effects due to cell replacement are related to the complexity of the pre-built host system. To effectively replace lost cells, transplanted ones should integrate within the host circuits and establish proper connections eventually reaching long-distance targets through the inhibitory white matter. So far, several transplantation strategies have focused on the more achievable 'paracrine' effect \[[@B14]\], in which transplanted cells act therapeutically through the secretion of diffusible factors. Several studies report a therapeutic effect of stem cells due to the trophic modulation of the neurodegenerated environment in different models of neurological disorders (that is, Parkinson's disease, stroke, and Huntington's disease) \[[@B15]\]. Proceeding beyond this strategy, stem cells can also be engineered to secrete selected molecules at the disease site \[[@B16]\]; human neural progenitor cells (hNPCs) modified by using lentivirus to secrete glial cell-derived neurotrophic factor (GDNF) integrated properly within ALS animal models. After transplantation into the spinal cord of *SOD1* (G93A) rats, a significant cell migration toward disease sites was observed together with efficient delivery of GDNF. A considerable preservation of MNs at early and end stages of the disease was shown within chimeric regions \[[@B17]\]. Similarly, hNPCs have been modified to release GDNF upon stimulation; cells have been transplanted in the striatum of a rodent model and could survive and effectively express GDNF, paving the way to further studies in Parkinson's disease animal models \[[@B18]\].

Recent years have brought several advances in the stem cell field, concerning methods of both reprogramming and differentiation. Stem cells can be defined by their ability to replicate indefinitely while maintaining the capacity to form cells of the three germinal layers (ectoderm, endoderm, and mesoderm lineages). The several categories of stem cells reflect the wide range of cell types derivable and the ways in which stem cells are obtained.

Human embryonic stem cells (hESCs) are derived from the inner cell mass of the blastocyst, they are pluripotent, and they can be maintained *in vitro* for a good period of time with a stable genetic background, providing a source of specialized human cells for biological and clinical applications \[[@B19],[@B20]\]. Directed differentiation of hESCs toward specific lineages is the first crucial step in order to extensively employ hESCs in early human development investigation as well as in potential future clinical applications. However, their use can raise ethical issues, and the therapeutic applications could imply risks of negative reaction, such as immune reactions or development of tumors or both \[[@B21]\].

Induced pluripotent stem cells (iPSCs) can be derived from patients' somatic cells by reprogramming them with specific factors \[[@B22]\]. They can be considered embryonic stem cell (ESC)-like cells, which express stem cell markers and have the ability to give rise to all three germ layers, bypassing the ethical concerns. Specific individual human-derived iPSCs provide the premises for cell replacement therapy without the related risks of immune rejection. Thus, human induced pluripotent stem cells (hiPSCs) constitute an appealing alternative source for MN differentiation. Different methods have been reported for iPSC derivation. Viral methods (generally the most efficient ones) present major risks related to the stochastic activation/inactivation of endogenous genes. Non-integrative methods (that is, proteins, RNAs, mRNAs, and plasmids carrying the reprogramming factors) have been developed to bypass this concern and facilitate the transition to clinical practice \[[@B23]\].

During the last decades, increasing efforts have been made to direct specific differentiation of stem cells toward neuronal lineages. Data from several studies reported that ESCs and iPSCs are responsive *in vitro* to the same developmental stimuli guiding neural specification *in vivo* and are able to give rise to differentiated neuronal cells with specific morphological and molecular signatures. Obtaining fully differentiated cells is crucial to model in simplified *in vitro* platforms the complex processes underlying physiological development and disease pathogenetic mechanisms, with the ultimate aim to find a cure for orphan disorders.

This could be particularly important for those pathologies, such as MNDs, for which obtaining affected relevant cells from human patients can be challenging. Indeed, some of the first reported examples about generating human disease-specific cells are related to MNDs \[[@B24],[@B25]\]. Many issues need to be addressed to effectively translate iPSCs to large-scale preclinical studies; among them is the assessment of standardized efficient protocols of differentiation and of homogenous parameters to evaluate the obtained cell phenotype. In the case of spinal MNs, efforts aiming to point out rapid and highly efficient differentiation methods are being pursued worldwide.

In the present review, we will first describe the fundamental steps regulating MN specification *in vivo*; data obtained from these studies have guided the assessment of experimental differentiation protocols *in vitro*. We will focus our attention on MN differentiation derived from hESCs and iPSCs; the most used methods of neural induction will be reviewed. Neural induction is the first crucial step to obtain neural progenitors through neural rosette and embryoid body (EB) formation. Then, neural progenitors can be differentiated with different protocols varying for rapidity and efficiency. We will give an overview of the most recent published methodologies together with the different methods of evaluation of obtained MNs. Finally, we will consider potential clinical applications of hiPSC/ESC-derived MNs with a focus on MND modeling and treatment, paying attention to the biological challenges that we need to address before translating promising preclinical data into clinical application.

Motor neuron development
========================

During embryogenesis, patterning and cell fate specification are regulated by the local production and secretion of protein morphogens and growth factors. Neurogenesis is the developmental process by which the whole nervous system is generated; it starts from the ectodermal plaque that folds over on itself, giving rise to the neural tube. The neural tube grows along rostrocaudal and dorsoventral axes, and during this process the cellular differentiation is induced by morphogenetic factors and signaling molecules secreted by neighboring cells (Figure [1](#F1){ref-type="fig"}) \[[@B26]\]. Morphogens induce the activation of intracellular pathways that, through the activation of specific transcriptional factors, cause a specific genetic expression that leads to cellular differentiation. In particular, specification of spinal MN fate is determined by three steps: neuralization, caudalization, and ventralization \[[@B27]\].

![**Schematic representation of the role of morphogens during neural tube formation*in vivo*.** Color gradients are indicative of the expression levels of each morphogen. Bone morphogen protein (BMP) can be found in high concentrations in the dorsal part of the neural tube (light green): its levels decrease along the ventral part. In contrast, Sonic hedgehog (Shh) is more concentrated in the ventral part (orange), but it is not expressed in the dorsal one. Fibroblast growth factor (FGF) is highly expressed in the anterior (purple) and posterior (dark green) parts of the neural tube. Retinoic acid (RA) levels of expression decrease in the posterior part (light blue), where high concentrations of both FGF and Wnt can be found. MN, motor neuron.](scrt476-1){#F1}

The term neuralization refers to the specification of the ectodermal cells toward epidermis or neural fate. This specification is influenced by the bone morphogen protein (BMP) that belongs to the transforming growth factor-beta (TGF-β) superfamily of proteins \[[@B28]\]. Therefore, neural induction is initiated through inhibition of both BMP and TGF-β/SMAD signaling \[[@B29]\]. Spinal MNs are diversified along the rostrocaudal axis by retinoic acid (RA) \[[@B30]\], which induces neuralization and caudalization and Wnt and fibroblast growth factor (FGF) signals \[[@B31]\] that promote an anterior or rostral pattern \[[@B32]\]. Ventral patterning is controlled by Sonic hedgehog (Shh) that directs ventralization of the spinal neural progenitor cell \[[@B33]\], whereas dorsal patterning is controlled by members of the BMP family \[[@B34]\].

BMP factors are selectively located in the 'roof plate' regions of the dorsal neural tube. Other growth factors are expressed specifically by the most ventral region ('floor plate'). The roof plate gives rise to the interneurons, whereas the region of floor plate is the site of origin of developing MNs. The dorsoventral axis of the neural tube is established by Wnt morphogenetic signaling gradients: high concentration of Wnt determinates the dorsal region, whereas Shh signaling defines the ventral region \[[@B35]\]. Wnt proteins are also involved in axon guidance within the spinal cord in an anterior-posterior direction \[[@B36]\].

Understanding pathways and specific morphogens that regulate MN development is crucial to replicate *in vitro* some of these physiological steps in order to obtain enriched MN populations starting from human iPSCs and ESCs. At present, there are many protocols that exploit morphogens or synthetic agonists to promote MN specification \[[@B37],[@B38]\].

Motor neuron generation from human pluripotent stem cells
=========================================================

Different methods for MN differentiation have been performed (Table [1](#T1){ref-type="table"}); here, we summarize a selection of the recently published and most significant protocols for obtaining a highly pure population of MNs differentiated from human pluripotent stem cells (hESCs and hiPSCs).

###### 

Experimental protocols for motor neuron induction from human embryonic and induced pluripotent stem cells

  **References**                                                **Starting cells**                **Neural induction**                                                                         **MN differentiation**                                             **MN maturation**                     **Duration**                                                                                                                                                                                                                                                                               
  ------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------- ------------
  Amoroso *et al*. \[[@B39]\]                                   ESCs and iPSCs                    ESC medium^a^                                                                                Y27632, bFGF, LDN193189, and SB435142                              Embryoid bodies                       Neural induction medium^b^                                                        RA, ascorbic acid, BDNF, C25II modified Shh, SAG, HAG, or purmorphamine    Neurobasal medium                                                 IGF1, GDNF, CNTF, and B27                                   20-30 days
  Boulting *et al*. \[[@B40]\]                                  ESCs and iPSCs                    ESC medium with 10% KO replacement                                                           bFGF and Y27632                                                    Embryoid bodies                       Neural induction medium^b^ supplemented with bFGF                                 RA, ascorbic acid, db-cAMP, and HAG                                        Neurobasal medium                                                 BDNF, GDNF, and CNTF                                        29 days
  Burkhardt *et al*. \[[@B41]\]                                 iPSCs                             DMEM/F12 supplemented with N2, B27, and NEAA                                                 Y27632, Dorsomorphin dihydrochloride                               Embryoid bodies                       DMEM/F12, GLUTAMAX, N2, B27 serum-free supplement, D-Glucose, and ascorbic acid   SAG, RA, and DAPT (only for 4 days)                                        DMEM/F12, GLUTAMAX                                                CNTF, BDNF, and GDNF                                        32 days
  N2, B27 serum free supplement, D-Glucose, and ascorbic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Corti *et al*. \[[@B25]\]                                     iPSCs                             DMEM/F12, NEAA, N2, and heparin                                                              RA                                                                 Neural rosette                        DMEM/F12, NEAA, N2, and heparin                                                   RA and Shh                                                                 DMEM/F12, NEAA, N2, and heparin                                   BDNF, GDNF, and IGF1                                        \~24 days
  Hester *et al*. \[[@B42]\]                                    ESCs and iPSCs                    DMEM/F12, N2, and 10% KO serum                                                               \-                                                                 Embryoid bodies then neural rosette   DMEM/F12 with N2                                                                  RA, Shh, forskolin, B27, and adenovirus                                    \-                                                                \-                                                          \~40 days
  Hu and Zhang \[[@B43]\]                                       ESCs                              DMEM/F12, KO serum replacement, NEAA, L-Glu, and BME                                         \-                                                                 Floating embryoid bodies              Neural differentiation medium (DMEM/F12, N2, NEAA, and heparin)                   Shh or purmorphamine, RA, B27, cAMP, ascorbic acid, BDNF, GDNF, and IGF1   Neural differentiation medium (DMEM/F12, N2, NEAA, and heparin)   cAMP, ascorbic acid, BDNF, GDNF, and IGF1                   \~40 days
  Karumbayaram *et al*. \[[@B44]\]                              iPSCs and ESCs                    ESC medium without FGF2                                                                      \-                                                                 Embryoid bodies/neural rosette        ESC medium without FGF2                                                           RA and purmorphamine                                                       DMEM/F12 and N2                                                   GDNF, BDNF, CNTF, Shh, and RA                               35-49 days
  Reinhardt *et al*. \[[@B29]\]                                 iPSCs and ESCs                    ESC medium^a^ and then expansion medium (DMEM/F12, N2, B27, pen/strep, and L-Glu)            For induction: SB435142, Dorsomorphine, CHIR, and purmorphamine    Embryoid bodies (smNPC)               Expansion medium (DMEM/F12, N2, B27, pen/strep, and L-Glu)                        Purmorphamine and RA                                                       Expansion N2, B27                                                 BDNF, GDNF, db-cAMP, RA, and purmorphamine                  \>40 days
  For expansion: ascorbic acid, CHIR99021, and purmorphamine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Sareen *et al*. \[[@B45]\]                                    iPSCs                             Neural differentiation medium (DMEM, B27, vitamin A, and N2)                                 RA                                                                 Embryoid bodies                       Neurobasal medium, B27, and N2                                                    RA and purmorphamine                                                       DMEM/F12 and B27                                                  RA, purmorphamine, db-cAMP, ascorbic acid, BDNF, and GDNF   \>40 days
  Takazawa *et al*. \[[@B37]\]                                  ESCs                              ESC medium^a^ and then DMEM/F12, N2, NEAA, L-Glu, and heparin                                Y27632, bFGF, and recombinant mouse Noggin                         Embryoid bodies                       Wnt3a-L-cell conditioned medium                                                   RA, ascorbic acid, db-cAMP, and recombinant mouse Shh (C25II)              Neurobasal medium with N2, B27, Glu, and NEAA                     Ascorbic acid, db-cAMP, RA, Shh, BDNF, GDNF, and IGF1       \>31 days
  Wada *et al*. \[[@B46]\]                                      ESCs                              ESC medium^a^ and FGF2                                                                       Noggin and dorsomorphin                                            Neural rosette                        DMEM/F12, N2B27                                                                   Shh or SAG, RA                                                             DMEM/F12, N2, B27, FGF2, and heparin                              GDNF, BDNF, and NT3                                         38 days
  FGF2, and EGF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Wichterle *et al*. \[[@B27]\]                                 mESCs                             DFK5 medium (DMEM/F12, L-Glu, pen/strep, BME, and insulin-transferrin- selenium supplement   RA, Shh, Hedgehog agonist (Hh-Ag1.3), or hedgehog antibody (5E1)   Embryoid bodies                       DMEM/F12 medium                                                                   \-                                                                         DMEM/F12                                                          GDNF, BDNF, CNTF, and NT3                                   \~25 days
  Zeng *et al*. \[[@B47]\]                                      iPSC (ESCs as positive control)   hESC medium^a^                                                                               N2 and heparin                                                     Neural rosette                        Neural medium^b^                                                                  RA, Shh, and FGF8                                                          Neural basal medium, N2, and B27                                  GDNF, BDNF, and IGF1                                        \>24 days

^a^Human embryonic stem cell (hESC) medium: Dulbecco's modified Eagle's medium (DMEM/F12), 20% knockout (KO) serum replacement, basal medium Eagle (BME), L-Glu, and non-essential amino acid (NEAA). ^b^Neural induction medium: L-Glu, NEAA, penicillin/streptomycin (pen/strep), heparin, and N2. BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; CNTF, ciliary neurotrophic factor; EGF, epidermal growth factor; ESC, embryonic stem cell; FGF, fibroblast growth factor; GDNF, glial cell-derived neurotrophic factor; HAG, human-specific Smo agonist; IGF1, insulin-like growth factor-1; iPSC, induced pluripotent stem cell; mESC, murine embryonic stem cell; MN, motor neuron; RA, retinoic acid; SAG, Smo agonist; Shh, Sonic hedgehog; smNPC, small-molecule neural precursor cell.

Neural induction
----------------

The term neural induction refers to the formation of neural progenitors deriving from pluripotent stem cells. There are several methods to promote neural induction; the majority include neural rosette and EB formation (Figure [2](#F2){ref-type="fig"}).

![**Generation of human motor neurons from human embryonic and induced pluripotent stem cells.** A schematic representation for motor neuron (MN) generation *in vitro* is shown. The first step in pluripotent stem cell - human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC) - differentiation is the attainment of embryoid bodies (EBs) in suspension or neural rosettes in adhesion conditions. These neural precursors can be successfully differentiated in MNs (characterized by specific features) with different multistage experimental protocols. hESC- or iPSC-derived MNs are a promising research tool to model and study *in vitro* pathological mechanisms underlying MN diseases in humans. These MNs could also represent an appealing source for autologous cell replacement. RA, retinoic acid; Shh, Sonic hedgehog.](scrt476-2){#F2}

Neural rosettes can be considered a stage at which neural stem cells exhibit a high proliferative potential and broad differentiation capacity along both neuronal and glial lineages in response to appropriate developmental signals \[[@B48]\]. Neural rosettes are defined by their specific cytoarchitecture, gene expression, and extrinsic growth requirements. To generate neural rosettes, hESCs and iPSCs are usually seeded on poly-L-lysine/laminin-coated culture dishes and maintained under adhesion conditions. Cells are usually plated in neurobasal medium supplemented with N2 and B27 for the growth and long-term viability of post-mitotic neurons. The medium can be additionally supplemented with mouse/human recombinant Noggin \[[@B37],[@B46]\] or Dorsomorphin, which are employed as inhibitors of BMP signaling to enhance neural induction \[[@B29],[@B38],[@B46]\]. Alternatively, stem cells can be cultured on stromal feeder \[[@B49]\] or transferred in modified TeSR1 medium until cells adhere and rosette structures appear \[[@B50]\].

Reinhardt and colleagues \[[@B29]\] reported the generation of hNPCs using only small molecules. These neural progenitors do not require manual selection and they are also able to differentiate into neural tube lineages, including MNs. The authors also hypothesized that Wnt, in combination with Shh, might contribute to the maintenance of neural precursors. Neural induction was promoted through inhibition of both BMP and TGF-β signaling using Dorsomorphin and SB43152. To stimulate the canonical Wnt signaling, CHIR99021, a GSK3β inhibitor, was added to the cell medium and the Shh pathway was stimulated by using purmorphamine.

In recent years, many groups have exploited protocols focused on the formation of EBs to differentiate stem cells into MNs. EBs are three-dimensional cell aggregates that grow spontaneously, self-assembling in suspension cultures. For EB formation, iPSCs or ESCs are detached from mouse embryonic feeder fibroblasts and cultivated onto ultralow adherent culture dishes. Cell culture medium is similar to the one used for hESC culture, supplemented with TGF-β and BMP inhibitors. Media usually contain Noggin or a small-molecule substitute, like Y-27632 \[[@B51]\] to increase cell survival, SB435142 and LDN193189 to promote neural induction \[[@B39]\], and FGF to enhance growth.

Some authors adopted a combination of the two methods: EBs were cultivated in a suspension environment and then the aggregates were dissociated and seeded on laminin/poliornithin-coated plates to form neural rosettes \[[@B25],[@B43]\].

Motor neuron generation
-----------------------

Thanks to the cultural background of developmental biology, it is known that MN differentiation *in vitro* appears to summarize the sequence of events physiologically involved in spinal cord development. In 2002, Wichterle and colleagues \[[@B27]\] were the first ones to exploit RA and Shh to differentiate mouse ESCs through EB formation; MN differentiation protocols for rodent ESCs were later adapted to promote MN commitment of hESCs as well. Wada and colleagues \[[@B46]\] differentiated hESCs toward MNs through neural rosette formation: neural precursors derived from hESCs were treated with 1 μM RA and 500 ng/mL Shh, resulting in large numbers of Tubulin β III^+^, Hb9^+^, Islet1^+^, and choline acetyltransferase-positive (ChAT^+^) neurons. Transcriptional upregulation of MN markers such as Islet 1, Hb9, and Olig2 was shown. Terminally differentiated neurons were Synapsin-positive and electrophysiologically active. MNs were capable of recreating neuromuscular junctions in culture with C2C12 myotubule cells. Overall, these data indicate that hESCs can differentiate into MNs that express specific molecular markers and have functional properties similar to those of physiologically developed MNs. Through the years, many reported protocols have tested different efficacious concentrations of the crucial signaling molecules, from 1 nM to 1 μM of RA and from 50 to 500 ng/mL of Shh \[[@B25],[@B39],[@B40],[@B45]\].

Another crucial variable to be modulated is the time of addition of the small molecules for differentiation. Hu and Zhang \[[@B43]\] reported a protocol starting from hESCs that were differentiated into MNs: cells were cultured for 4 days in hESC medium and in neural differentiation medium thereafter. In the second week, aggregates attached to the surface of culture dishes and possessing features of neuroepithelial rosettes could be isolated by manual selection. The authors reported that the early neuroepithelial cells Olig2-positive at day 10 were much more responsive to RA; thus, RA was added at day 10 in their protocol. These Olig2-expressing cells then differentiated to spinal motoneurons in the fifth week and expressed transcription factors such as Hb9 and Islet1. They reported that the optimized protocol typically generates over 50% of Hb9-expressing motoneurons from the original hESC progenies.

Another variable to be considered is the natural habit of human stem cells to differentiate into caudal/rostral subtypes giving rise to medial/lateral column as well as cranial MNs. Similarly, the selective differentiation signal inducing the development of specific neuronal subtypes within the wide range of spinal cord MNs warrants further studies to be extensively applied in *in vitro* studies and cell therapies. The manipulation of Hox gene network specifying columnar and pool MN identity may be fundamental to selectively modulate the differentiation of precursor cells into specific MN subtypes. Recently, Amoroso and colleagues \[[@B39]\] systematically compared the ventralizing activity of three Smoothened agonists using a standard RA/Shh protocol involving all-trans RA and a modified Sonic hedgehog (Shh-C25II) protein as a benchmark for differentiation of hESCs into MNs. To evaluate MN numbers, they relied on the HUES3 Hb9:GFP reporter line which contains a transgene expressing green fluorescent protein (GFP) under the control of the MN-specific Hb9 promoter. HUES3 cells were electroporated with a plasmid carrying a neomycin resistance cassette and the GFP coding sequence upon transcriptional control of Hb9 promoter restriction fragment. In this way, stem cells were engineered in order to express GFP under the control of the MN-specific reporter Hb9. This strategy allows the study of cell morphology and differentiation in culture and their tracing *in vivo*. However, it has to be considered that this marker does not provide any information on motor neuronal subtype and the fluorescence of GFP could give false-positive results due to the GFP long half-life. Very few GFP^+^ cells were observed in the absence of exogenous Shh agonists. Recombinant Shh and human-specific Smo agonist each gave rise to less than 10% GFP^+^ cells. In contrast, the Smo agonist (SAG) alone gave rise to 16% ± 4% GFP^+^ cells and purmorphamine alone induced 22% ± 6%. RNA-seq analyses revealed an enrichment of spinal MN markers and the expression of cholinergic genes in cells treated with SAG and purmorphamine compared with only Shh-treated ones. This work exploited non-viral protocols of differentiation, characterized also by relatively high rapidity and efficiency. Not less important, Amoroso and colleagues \[[@B39]\] made great efforts in selecting and validating a pool of specific markers to evaluate the cell phenotype: Hb9 and ISL1 were found to be alternatively expressed in approximately half of the cells, not always co-expressed as originally believed. Moreover, this differentiation method starting from hESCs resulted in the generation of MNs expressing FOXP1 (68% ± 4%), which is a marker of limb muscle-innervating lateral motor column neurons. This regional sub-specification could be important for disease modeling studies.

Many other differentiation cocktails have been reported to share the objective of gaining highly enriched spinal cord motor neuronal populations: supplementing RA and Shh with B27 \[[@B43],[@B46]\], cAMP \[[@B37],[@B40],[@B45]\], heparin, brain-derived neurotrophic factor (BDNF), and ascorbic acid \[[@B37],[@B40],[@B45]\]. López-González and colleagues \[[@B52]\] analyzed the effect of progesterone and 17β-estradiol on MN differentiation of HBG3 ESCs. Progesterone treatment during MN differentiation at EB stage, combined with RA and Shh, induced higher proportions of MN compared with RA/Shh alone \[[@B52]\].

The discovery and establishment of the use of iPSCs provided further advances in the field; it has become possible, by using hiPSCs, to produce MNs carrying the specific combination of genetic variants that caused neurodegeneration in a single patient. A multistage MN differentiation protocol starting from SMA patient-derived iPSCs has been performed by Corti and colleagues \[[@B25]\]. For MN generation, iPSCs derived from patients with SMA were grown in a neuronal medium supplemented with N2 and heparin. After 10 days, RA (0.1 μM) was added for caudalization, and at day 17 the clusters of posteriorized neuroectodermal cells were resuspended for a week in the same medium with RA (0.1 μM) and Shh (100 to 200 ng/mL). On day 24, BDNF, GDNF, and insulin-like growth factor-1 were added for MN maturation. Derived human MNs were characterized by the expression of specific markers and carried the pathological hallmarks of SMA disease.

This study provided important data on the potential applications of stem cells both as *in vitro* models of disease and as a feasible therapeutic approach. In regard to the former, generated MNs presented features indicative of mature lineage and spinal MN commitment such as HB9/ISLET1 and SMI32. The *in vitro* differentiation protocol generated a mixed cell population, including non-motor neuronal cells. To further isolate and purify MNs, a physical strategy based on gradient centrifugation and leading to an enriched MN population was exploited \[[@B25]\]. Moreover, SMA-iPSC-derived MNs showed shorter axonal length, smaller growth cones, and impaired ability to form neuromuscular junctions compared with wild-type cells, hallmarks of MN disease. In regard to the latter, reprogrammed cells have been obtained with non-viral non-integrating methods, which could be suitable for human therapy uses in the future. Once reprogrammed cells were transplanted into the mouse model, there were no major signs of rejection but rather a proper engraftment was documented with even a partial rescue of the diseased phenotype.

Similarly, different methods have been performed for MN induction starting from hiPSCs derived from patients affected by ALS. Sareen and colleagues \[[@B45]\] generated iPSC-derived MNs from patients with ALS by growing iPSCs for 6 days in suspension with neural differentiation medium enriched with RA for EB formation. At day 17, cells were treated with neural induction medium supplemented with RA and purmorphamine for 8 days. Then EBs were dissociated and single cells were plated in medium with B27, RA, purmorphamine, db-cAMP, ascorbic acid, BDNF, and GDNF for 2 to 7 weeks. Derived MNs recapitulate the features of ALS disease and can be employed to investigate cellular degeneration processes and test new therapeutic compounds.

Derived motor neuron evaluation
-------------------------------

The increasing expertise in differentiating MNs with different experimental protocol variables emphasizes the necessity for continuous evaluation of derived MNs. To exploit human stem cell-derived MNs in regenerative medicine or in MND *in vitro* modeling, it is first necessary to evaluate their proper differentiation, assessing that they have the same features as MNs *in vivo*. An efficient MN differentiation starting from human ESC and iPSC lines can be assessed by evaluation of those features that are the hallmarks of MNs *in vivo* (that is, marker expression, morphology, and functional properties) (Figure [2](#F2){ref-type="fig"}). The authors demonstrated that hESC- and hiPSC-derived MNs are characterized by the expression of the same specific markers previously assessed in human MNs *in vivo*\[[@B25]-[@B27]\]. Indeed, the expression of MN post-mitotic markers such as Hb9, HoxC8, ChAT, and SMI-32 was evaluated by immunocytochemistry assays, as was the expression of MN progenitor markers like Pax6, Nestin, Olig2, and Islet1/2 and pan-neural markers such as β-tubulin and anti-microtubule-associated protein 2 \[[@B25],[@B29],[@B39],[@B42],[@B45]\].

Karumbayaram and colleagues \[[@B44]\] demonstrated that MNs derived through neural rosette and EB formation expressed MN progenitor markers (that is, Olig2 and Nkx6.1) and also showed an enrichment of mature markers like β-tubulin, ChAT, and Islet1. To further characterize the expression of these markers in an unbiased manner, authors usually perform Western blot, PCR - quantitative reverse transcription-PCR and reverse transcription-PCR - and whole-transcriptome sequencing or RNA-seq to detect an enrichment of spinal MN markers (Islet1, Islet2, and Hb9) and of CHAT, CHT1, VACHT, CHRNA3, CHRNA4, and CHRNB2, which are indicative of cholinergic identity \[[@B27],[@B39]\].

In several studies, stem cells were manipulated in order to express GFP driven by an MN-specific reporter. A reporter specific for activity of Hb9 which encodes for a transcription factor specifically expressed by mature MNs is most commonly used because of its relatively high specificity and assessed staining.

Hb9-driven GFP reporter is usually transfected into stem cells, allowing the identification of MNs in which Hb9 is transcriptionally active. This technique facilitates cell study in culture and cell tracing *in vivo*. Hb9:GFP stem cells can be studied for their maturation in cellular morphology (that is, branching and neurite outgrowth) and increased soma area over time \[[@B29],[@B39],[@B44]\]. Other authors developed Olig2:GFP lines in which an enhanced GFP cassette was inserted to the Olig2 locus of hESCs to target MN progenitors \[[@B53]\]. Electrophysiological analysis, including calcium imaging and whole-cell patch clamp, showed that stem cell-derived MNs become electrically active with prolonged time in culture and are responsive to glutamate agonist \[[@B27],[@B34],[@B38],[@B39],[@B49]\]. Takazawa and colleagues \[[@B37]\] observed electrophysiological changes associated with maturation of MNs differentiated from stem cells, which included decreasing input resistance and increasing action potential firing frequency. Furthermore, these cells showed two peculiar characteristics of spinal MNs *in vivo*: spike frequency adaptation and rebound action potential firing \[[@B37]\].

*In vivo* morphological analyses can consist of xenotransplants by injection of stem cell-derived MNs (usually Hb9:GFP^+^ to be easily traced) into animal models. Pluripotent stem cell-derived MNs demonstrated the ability to project axons outside of the CNS through the ventral (and sometimes dorsal) roots and to follow proper neural paths when transplanted into spinal cord of developing chickens \[[@B39]\] or mice \[[@B25],[@B29]\]. Furthermore, Corti and colleagues \[[@B25]\] demonstrated that engrafted GFP-MNs co-expressed pan-neuronal-specific markers and ChAT, formed new neuromuscular junctions with skeletal muscles, and, once transplanted into SMA model mice, induced an improvement of neuromuscular phenotype and survival.

Clinical perspectives
=====================

Disease modeling
----------------

Disease modeling represents an interesting possibility of application of human stem cell-derived MNs: with the optimization of standardized protocols for stem cell differentiation, it has become achievable to produce human MNs in substantial amounts for elucidating *in vitro* basic disease processes. Stem cells could also be manipulated in order to express mutant genes related to MNDs \[[@B54],[@B55]\].

The discovery of reprogramming methods using specific factors and the subsequent derivation of the first patient-specific hiPSC lines provided a further step in this direction.

iPSCs can be employed to derive human MNs *in vitro* and thus address specific questions about altered neuronal differentiation and function that might cause the development of diseases such as ALS, SMA, and many others. The possibility to recreate *in vitro* a reliable model of human disease is valuable, as there have been many examples of therapeutic approaches that were relatively efficacious in animal models but unfortunately did not translate well to patients \[[@B7]\].

Burkhardt and colleagues \[[@B41]\] reprogrammed fibroblasts to iPSCs derived from a large cohort of healthy controls and ALS patients and differentiated them into MNs. The authors reported that MNs derived from three patients with SALS possessed *de novo TDP-43* aggregation and that these aggregates summarized pathological features in post-mortem tissue from one of the three patients from which iPSCs were derived. The authors then performed a high-content chemical screen by using the TDP-43 aggregate endpoint in both lower MNs and upper derived MNs identifying US Food and Drug Administration-approved small-molecule modulators.

Corti and colleagues \[[@B25]\] generated iPSCs from SMA patients with non-viral methods resulting in cells free from vectors and transgenic sequences. SMA-iPSCs were then differentiated into MNs with a multistage differentiation protocol involving RA and Shh. MNs generated from SMA-iPSCs carried specific disease-related features suggestive of selective MN degeneration such as a reduction in MN survival and size as well as in axonal growth and neuromuscular junction formation. Oligodeoxynucleotides to SMN2 were generated with a stable genetic modification of a single nucleotide in exon 7, leading to the modification of SMN2 coding region. As a consequence, exon 7 was rescued, resulting in a greater production of full-length SMN2. Phenotypes of MNs derived from corrected and untreated SMA-iPSCs were compared: gene correction with oligonucleotides rescued neuropathological features in SMA MNs and correlated with SMN expression. Transcriptional differences in the SMA-iPSC MNs in comparison with treated SMA-iPSC MNs were evaluated, revealing alterations in a subset of genes involved in RNA metabolism, MN development, and axonal guidance.

Thus far, various iPSC lines from patients with various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, have been generated \[[@B56]-[@B58]\]. Patient-derived stem cells could be one of the best complementary approaches to the use of reliable animal models to identify and test therapeutic compounds for neurological disorders.

Therapeutic transplants of human motor neurons
----------------------------------------------

Cell therapy in neurodegenerative disorders acts by introducing functional cells in order to rescue the function of damaged neural tissues. Transplantation of hESC-derived MNs into the developing chick embryo resulted in correct engraftment, maintenance of motoneuron identity and long-distance axon elongation outside the CNS, reaching properly peripheral muscular targets \[[@B49]\]. Transplantation into the adult rat spinal cord resulted in neural engraftment, including a great number of human MNs with sprout of ChAT^+^ fibers. These data suggest that hESC-derived MNs may be able to project toward the ventral root through the adult spinal cord, similarly to the embryonic chick spinal cord even if with a different time scale. This study provided evidence for *in vivo* survival of hESC-derived MNs, a crucial requirement for future preclinical applications.

hiPSCs are similar to hESCs, and the experimental strategies developed for hESCs could be applied to iPSCs without major modifications. In addition, hiPSCs do not have issues in the immunologic compatibility between donors and recipients reported in hESCs \[[@B57]\]. Thus, they have been investigated as a promising source of autologous cells for transplant therapy in neurological disorders. iPSCs from patients with SMA (SMA-iPSCs) were generated by using non-viral, non-integrating episomal vectors: *SMN2* gene was converted into an *SMN1*-like gene with a strategy based on the use of single-stranded oligonucleotides \[[@B25]\]. *In vivo* experiments after transplantation into the spinal cord of transgenic SMA mice showed that iPSC-derived MNs can survive and integrate into the spinal cord of SMA mice and ameliorate the SMA type I phenotype. Transplanted SMA mice had a longer survival (about 50%) compared with vehicle-treated mice, a beneficial effect that was more relevant with treated SMA-iPSC MNs than with untreated ones \[[@B25]\].

These appealing premises for clinical therapies have to be modulated by the presence of crucial issues to be addressed before effectively translating cell-mediated approaches to the clinic. Important concerns are related to the generation and preparation of cells under good manufacturing practice (GMP). It has been demonstrated that ESCs can be generated without the use of reagents of animal origin (xenobiotics); however, the derivation of patient-specific iPSCs usually requires methods of reprogramming that are not performed in xeno-free conditions. iPSCs generated with viral methods present major risks related to the stochastic activation/inactivation of endogenous genes. Non-integrative methods (that is, proteins, RNAs, mRNAs, and plasmids carrying the reprogramming factors) have been improved to bypass this concern and facilitate the transition to the clinic \[[@B23]\]. Neural stem cells to be transplanted can be obtained also by direct reprogramming (induced neural stem cells, or iNSCs): experimental protocols present fewer passages in comparison with the generation of iPSCs, thus lessening the necessity of different quality-check points \[[@B59]\]. On the other hand, iNSCs are a rather new source of stem cells and consequently generation methods still need to be standardized together with a precise evaluation of the obtained phenotype \[[@B59]\]. In general, protocols of differentiation toward a specific lineage, including rigorous methods of data homogenization and standardization in order to be reproducible, should be implemented. Several xeno-free media preparations are commercially available, together with GMP feeders \[[@B23]\]. Differentiated phenotype needs to be rigorously evaluated, and different assessment methods are usually combined to limit eventual unspecific staining. Indeed, GMP optimized techniques to trace and evaluate the state of transplanted cells will be necessary after clinical translation. Finally, obtained cells should undergo standardized quality control to assess viability, sterility, and proper cell conformation (that is, karyotype analysis, specific marker evaluation, and absence of xenobiotic contamination) \[[@B23]\].

Concerns related to the host immunorejection could be bypassed with the use of autologous cells, such as iPSCs. However, studies rigorously assessing iPSC immunogenicity still need to be performed, and results could vary on the basis of cell preparation protocols.

The clinical perspectives on the use of cell-based therapies have to be calibrated on the basis of the previous issues: the premises for future treatments are great but need to be thoroughly tested by standardized *in vitro* studies at first and then by a rigorously assessed clinical trial in humans.

Despite many aspects to be cleared and certainly worthy of further studies (that is, ability of transplanted MNs to survive, integrate, and project their axons for long-distance innervating properly peripheral targets), these preliminary results open the way to a future in which human pluripotent stem cells may provide a source of healthy MNs for therapeutic transplantation for SMA and other MNDs.

Conclusions
===========

The potential of human pluripotent stem cells to treat patients with neurodegenerative disease is enormous. Stem cells can be introduced into clinical applications in several different ways, such as disease modeling, drug screening, and cell replacement therapy.

The development and optimization of non-viral methods of stem cell reprogramming will allow clinicians to bypass concerns related to random viral integration. The use of autologous patient cells could also alleviate problems associated with host immunorejection. In regard to the production of differentiated cells, it is crucial to assess protocols with high efficiency allowing a large-scale production for quality-control assessment. A very recently published study reported the generation of MNs from iPSCs in 20 days \[[@B60]\]. In view of future clinical applications, it is necessary to integrate efficiency and rapidity of production with constant attention to working under GMP conditions, exploiting xeno-free media, and conducting a careful quality-control assessment. Recent progress in stem cell research has opened new perspectives for *in vitro* generation of large numbers of various neural cell types and for their use in the repair of the nervous system. Advances in obtaining and understanding MNs have been made in recent years; however, some aspects still need to be investigated. Among them, the molecular signature of MN development and specification into different subtypes *in vivo* is only partially known. In regard to different methods exploited to produce MNs, extensive applications need a precise consideration of the experimental conditions for cell plating and culturing. Moreover, challenges such as those ensuring clinical safety should be overcome. Even though it may take quite a long time to address all of these questions, the establishment and optimization of human stem cell differentiation protocols to develop hiPSC-based clinical applications may hold the key to curing neurodegenerative disorders.
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